Guidelines
Below you can find all of the clinical guidelines and pathways involving medicines which are approved for use across the North East and North Cumbria ICS.
For legacy guidelines you may still need to visit the previous APC websites until a single NENC ICB version is available.
| Title | Documents | Decision | Date | |
|---|---|---|---|---|
Cardiovascular |
||||
| Northern England Evaluation and Lipid Intensification guideline | NEELI 2025 version 061125 - approved Dec 2025 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 11/12/2025 | |
Central Nervous System |
||||
| Oral Antipsychotics - Safe Prescribing Pathway | NENC Oral antipsychotics - Safe Prescribing - v1.2 - approved March 2026 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 26/03/2026 | |
| NENC ICB Cognitive Impairment Dementia Educational and Clinical support document | NENC ICB Cognitive Impairment Dementia Educational and Clinical support document - approved Oct 2025 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 20/10/2025 | |
| North East North Cumbria (NENC) ICB Medicines Committee Position Statement on Prescribing in Persistent Pain | NENC ICB position-statement-non-palliative-care-use-of-opiates - update Feb 2026 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 26/03/2026 | |
| NENC Clinical Pain Network Position Statement on Chronic Pain Guidelines | NENC Clinical Pain Network Position Statement on Chronic Pain Guidelines - approved | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 10/10/2024 | |
|
Updated 27/07/2026 |
NENC Agomelatine - Prescribing and Monitoring in Adults - Information for Primary Care | NENC Agomelatine - Prescribing and Monitoring in Adults - Information for Primary Care - v2 - approved July 2026 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 23/07/2026 |
| NENC Bupropion for resistant depression - Information for Primary Care | NENC Bupropion information sheet for primary care - approved Feb 2025 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 13/02/2025 | |
| NENC Clozapine Supporting guidance for primary care | NENC Clozapine Supporting guidance for primary care - v2 - approved March 2026 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 26/03/2026 | |
|
Updated 27/07/2026 |
North-East and Cumbria Adult Headache Guideline | North-East and North Cumbria Adult Headache Guideline - June 2026 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 23/07/2026 |
| NENC Gabapentinoid dose reduction when prescribed for pain | NENC GABAPENTINOID DOSE REDUCTION WHEN PRESCRIBED FOR PAIN - approved Jan 2026 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 22/01/2026 | |
|
New 27/07/2026 |
NENC ICB Position Statement on Promethazine in Primary Care | NENC ICB Position Statement on Promethazine in Primary Care - approved July 2026 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 23/07/2026 |
Respiratory |
||||
| NENC COPD Guideline | NENC COPD management guidelines ICB version 1.3 - approved Feb 2025 - updated 18.2.26 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 13/02/2025 | |
| NENC Management of COPD Exacerbations - Rescue medication in primary care | NENC Management of COPD exacerbation rescue medication in primary care - approved Dec 2025 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 11/12/2025 | |
|
Updated 27/07/2026 |
NENC Adult Asthma Guideline | NENC Adult asthma guidelines v2.2 approved July 2026 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 23/07/2026 |
| NENC Asthma Prescribing Guidelines for Children and Young People 2 to 5 years | NENC Asthma Prescribing Guidelines for Children and Young People 2 to 5 years - approved Jan 2026 v1 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 22/01/2026 | |
| NENC Asthma Prescribing Guidelines for Children and Young People 6-11 years | NENC Asthma Prescribing Guidelines for Children and Young People 6-11 years - approved Jan 2026 v1 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 22/01/2026 | |
|
Updated 27/07/2026 |
NENC Asthma Prescribing Guidelines for Children and Young People 12 to 17 years | NENC Asthma Prescribing Guidelines for Children and Young People 12 to 17 years - approved July 2026 v1.1 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 23/07/2026 |
| NENC Nebulised Gentamicin - Information for Primary Care | NENC Nebulised-Gentamicin-Information-for-Primary-Care - approved Oct 2025 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 09/10/2025 | |
| NENC Deprescribing considerations for adults with asthma currently prescribed theophylline | NENC Deprescribing considerations for adults with asthma currently prescribed theophylline - approved Dec 2025 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 11/12/2025 | |
Infection |
||||
| North East North Cumbria (NENC) ICB Medicines Committee Position Statement on Antimicrobial Stewardship | NENC-ICB-position-statement. Antimicrobial Stewardship - v1.1 Dec 2025 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 22/01/2026 | |
| Cellulitis Diagnosis and Management in Ambulatory Adults in primary care; Supporting Information - NENC ICB | Cellulitis Diagnosis and Management in Ambulatory Adults in primary care; Supporting Information - NENC ICB - FINAL version 5 | Approved by NENC Medicines Subcommittee | 16/09/2024 | |
| NENC Penicillin Allergy Assessment primary care for adult patients - approved May 2026 | NENC Penicillin Allergy Assessment primary care for adult patients - approved May 2026 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 04/06/2026 | |
Endocrine |
||||
| NENC Guidelines: Self-Monitoring of Blood Glucose and Ketones in Diabetes | NENC Guidelines Self-Monitoring of Blood Glucose and Ketones in Diabetes - approved Dec 2025 (updated Feb 2026) | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 11/12/2025 | |
| Diabetes goes GREEN - Blood Glucose Meters Recycling Methods | Diabetes goes GREEN - Blood Glucose Meters Recycling Methods v2.5 - NENC CEG approved June 2025 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 12/06/2025 | |
| NENC Position Statement on Safety Needles and Safety Lancets | Safety needles and lancets NENC position statement V1 - approved Dec 2025 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 11/12/2025 | |
| NENC Guideline For Use Of Sodium Glucose Co transporter 2 Inhibitors (SGLT2i) | NENC regional SGLT2 top tips v4 - approved Dec 2025 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 11/12/2025 | |
| NENC ICB - Management of the Menopause | NENC-Menopause-guidance-FINAL Sept 24 - approved | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 10/10/2024 | |
| NENC/Northern Cancer Alliance - Unscheduled Bleed on HRT British Menopause Society guidelines summary for GPs August 2025 | BMS Guidelines(summary for primary care)unscheduled bleeding on HRT July 2025 (final)V3 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 12/06/2025 | |
| Dienogest for the treatment of endometriosis - NENC Green+ Information leaflet | Dienogest NENC Green+ information leaflet draft - v1 - approved Aug 2025 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 14/08/2025 | |
| Endocrine Guidelines for Treatment of Gender Incongruence Northern Region Gender Dysphoria Service | FINAL Endocrine treatment for gender incongruence NRGDS October 2025 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 14/08/2025 | |
Blood and Nutrition |
||||
| NENC Guidelines for the appropriate prescribing of Oral Nutritional Supplementation in the management of adults at risk of undernutrition in primary care | Guidance appropriate ONS prescribing ICB FINAL - approved v1.1 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 10/10/2024 | |
| Management of Acute Hypomagnesaemia in Adults in Primary Care | NENC ICB Management of Hypomagnesaemia in Adults in Primary Care - approved v1.1 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 10/10/2024 | |
|
Updated 27/07/2026 |
NENC Guidelines for the recognition and management of non-IgE cow's milk allergy (CMA) in infants | NENC Guidelines for the recognition and management of non-IgE cows milk allergy (CMA) in infants v1.3 July 2026 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 23/07/2026 |
| NENC Guideline for the Recognition and Management of Faltering Growth in Infants and Young Children | NENC ICB Faltering Growth Guideline - approved May 2026 NENC_Faltering_Growth_Clinician_Infographic 5.5.26 final | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 04/06/2026 | |
| NENC Primary Care Management of Adult Vitamin D Deficiency | NENC Primary Care Management of Vitamin D Deficiency in adults - Mar 2025 - Approved | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 10/04/2025 | |
| NENC Position Statement for self care with Vitamin D | NENC Position Statement for self care with Vitamin D - approved Aug 2025 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 14/08/2025 | |
| NENC Guideline for the diagnosis, management and review of Vitamin B12 in over 16s | NENC ICB Vitamin B12 guidelines v1.1 approved November 2025 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 12/06/2025 | |
|
New 27/07/2026 |
NENC ICB Position Statement Primary Care Prescribing of Vitamin B12 | NENC ICB Position Statement Primary Care Prescribing of Vitamin B12 - approved July 2026 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 23/07/2026 |
| NENC ICB Gluten-Free Prescribing Policy | NENC ICB Gluten Free Policy - approved Jan 2026 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 22/01/2026 | |
Musculoskeletal and Joint Diseases |
||||
| NENC guideline for management of osteoporosis in primary care | NENC ICS guideline for management of osteoporosis in primary care - approved Jan 2026 v9.1 (updated March 2026) | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 26/03/2026 | |
| Patient information leaflet for changing brands of denosumab | Patient Information Leaflet -Changing Brands of Denosumab | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 22/01/2026 | |
| Biosimilar denosumab 60mg brand switch for use in osteoporosis - FAQs for Primary Care | Denosumab 60mg biosimilar switch FAQs for primary care_ | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 22/01/2026 | |
Obstetrics, gynaecology, and urinary tract |
||||
| North of Tyne, Gateshead and North Cumbria Urinary Catheter Care Product Formulary 2023 | NoTGNC Catheter Formulary 2023 V7 | Approved | 05/12/2023 | |
| North of Tyne, Gateshead and North Cumbria Urinary Continence Enablement Products and Devices Formulary Guideline | NoTGNC Urinary Continence Enablement Products and Devices Formulary Guideline V6 - approved | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 10/10/2024 | |
| NENC Urinary incontinence pathway for women | NENC Urinary incontinence pathway for women - NENC ICB Clinical Effectiveness Group Approved 091025 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 09/10/2025 | |
Renal |
||||
| SGLT2-inhibitors and Chronic Kidney Disease - Patient Information Leaflet | SGLT2 CKD PIL NTAG v1 - reviewed July 2025 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 14/08/2025 | |
| Finerenone for treating chronic kidney disease in people with type 2 diabetes | NENC Finerenone_CKD_type 2 diabetes_v6 - approved March 2026 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommitte | 26/03/2026 | |
Miscellaneous |
||||
| Abnormal Liver blood test Guidelines NENC Hepatology Network V3.1 | Abnormal Liver blood test Guidelines NENC Hepatology Network V3.1 01-08-2024 | Approved for hosting on NTAG website. | 08/04/2024 | |
|
Updated 27/07/2026 |
NENC Position statement on the prescribing of branded generic medication | NENC-Position-statement-on-Branded-Generics-v3-approved-July 2026 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 23/07/2026 |
| NENC ICB Position Statement - Prescribing of Oral Iron Supplementation for Iron Deficiency Anaemia (IDA) | NENC ICB Iron position statement - FINAL | Approved by NENC Medicines Subcommittee | 16/09/2024 | |
| Emollient Prescribing Guideline and Formulary North East North Cumbria | Emollient Guidance NENC - Final 2024 - approved Oct 2024 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 10/10/2024 | |
| NENC Statement on Primary Care Prescribing of Over The Counter (OTC) Medications | NENC Statement on Primary Care Prescribing of Over The Counter (OTC) Medications 2024 - approved | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 12/12/2024 | |
| NENC Prescribing Guideline for Management of Stoma (Colostomy, Ileostomy and Urostomy) in adult patients | Prescribing Guideline for Stoma Care in Adults NENC - approved Feb 2025 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 13/02/2025 | |
| NENC Guidance on Seven-Day Prescriptions and Monitored Dosage Systems (MDS) | NENC 7 day prescribing MDS - approved April 2025 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 10/04/2025 | |
| North East and North Cumbria End of Life Care Symptom Control Guidelines | https://northeastnorthcumbria.nhs.uk/here-to-help-you/palliative-and-end-of-life-care/ | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 14/08/2025 | |
|
Updated 27/07/2026 |
NENC Position Statement on Medication Supply for Maternity Patients in Community | Currently being reviewed and updated | 23/07/2026 | |
| NENC Position statement on Third Party ordering of prescriptions | NENC Position statement on Third Party ordering of prescriptions - approved Jan 2026 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 22/01/2026 | |
| Northern Cancer Alliance Male and registered male at birth breast symptoms pathway | Northern Cancer Alliance Male and registered male at birth breast symptoms pathway - approved Jan 2026 | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 22/01/2026 | |
| Northern Cancer Alliance Breast cancer chemoprevention treatment pathway for those moderate or high risk of future breast cancer | 2025 Primary Prevention referral pathway V3 - FINAL | Approved by NENC Clinical Effectiveness and Governance (CEG) Subcommittee | 14/08/2025 |